Biohaven is powering ahead with its bold ambition to sharply reduce R&D spending—even as analysts warn the company will need ...
Futurism on MSN
Researchers Get Human Brain Cells Running Doom
"If the neurons fire in a specific pattern, the Doom guy shoots." The post Researchers Get Human Brain Cells Running Doom ...
BioAtla is laying off 70% of its workforce as the antibody biotech mulls whether to sell off its remaining assets. | BioAtla ...
A Senate hearing probed whether the Food and Drug Administration's process for approving rare-disease therapies is ...
A “living drug” was developed as a cancer treatment. Now it is showing promise for conditions, such as lupus and multiple ...
A leading oncologist proposes classifying metastatic cancer by molecular alterations rather than organ origin, arguing that the shift could accelerate drug access.
Good morning, and welcome once again to TD Cowen's 46th Annual Healthcare Conference. I'm Phil Nadeau, one of the biotech analysts here at Cowen, and it's my pleasure to do a fireside chat with ...
Regencell Bioscience (RGC 4.01%) is an early-stage bioscience company. That alone should be enough to keep most investors on ...
Motlagh also condemned a recent maritime attack on an Iranian vessel returning from a military exercise in India, which he claimed resulted in significant casualties.
Comfort with ambiguity isn’t about tolerance for chaos. Rather it's an opportunity to be creative, craft a vision, and build ...
Rare Disease Day is held on the last day of February to raise awareness for rare diseases and address drug development ...
The structures that UpNano produces in the 3D printer are so small that they are recognizable neither with the naked eye nor ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results